Home

Kent Temporizador Mono cowboy rägn kappa luz de sol Rebajar ajo

REVISTA ESPAÑOLA DE
REVISTA ESPAÑOLA DE

XXXVII Congreso SETH 2021.indd
XXXVII Congreso SETH 2021.indd

EL VALOR DEL MEDICAMENTO DESDE UNA PERSPECTIVA SOCIAL
EL VALOR DEL MEDICAMENTO DESDE UNA PERSPECTIVA SOCIAL

Comunicaciones orales
Comunicaciones orales

Optimized ACE2 decoys neutralize antibody-resistant SARS-CoV-2 variants  through functional receptor mimicry and treat infection in vivo | Science  Advances
Optimized ACE2 decoys neutralize antibody-resistant SARS-CoV-2 variants through functional receptor mimicry and treat infection in vivo | Science Advances

Frontiers | The Mechanism of Lung and Intestinal Injury in Acute  Pancreatitis: A Review
Frontiers | The Mechanism of Lung and Intestinal Injury in Acute Pancreatitis: A Review

A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2  variants | Nature Communications
A broadly neutralizing humanized ACE2-targeting antibody against SARS-CoV-2 variants | Nature Communications

Engineered extracellular vesicles directed to the spike protein inhibit  SARS-CoV-2: Molecular Therapy - Methods & Clinical Development
Engineered extracellular vesicles directed to the spike protein inhibit SARS-CoV-2: Molecular Therapy - Methods & Clinical Development

MADS NØRGAARD – COPENHAGEN – MADS NØRGAARD - COPENHAGEN
MADS NØRGAARD – COPENHAGEN – MADS NØRGAARD - COPENHAGEN

XXXVII Congreso SETH 2021.indd
XXXVII Congreso SETH 2021.indd

EL VALOR DEL MEDICAMENTO DESDE UNA PERSPECTIVA SOCIAL
EL VALOR DEL MEDICAMENTO DESDE UNA PERSPECTIVA SOCIAL

Frontiers | Immunopathogenesis of Different Emerging Viral Infections:  Evasion, Fatal Mechanism, and Prevention
Frontiers | Immunopathogenesis of Different Emerging Viral Infections: Evasion, Fatal Mechanism, and Prevention

Monoclonal antibodies targeting two immunodominant epitopes on the Spike  protein neutralize emerging SARS-CoV-2 variants of concern - eBioMedicine
Monoclonal antibodies targeting two immunodominant epitopes on the Spike protein neutralize emerging SARS-CoV-2 variants of concern - eBioMedicine

XXXVII Congreso SETH 2021.indd
XXXVII Congreso SETH 2021.indd

Guideline Therapeutics and COVID-19: living guideline
Guideline Therapeutics and COVID-19: living guideline

RESÚMENES DEL XLII CONGRESO DE LA SOCIEDAD ESPAÑOLA DE NEFROLOGÍA Y VII  IBEROAMERICANO DE NEFROLOGÍA
RESÚMENES DEL XLII CONGRESO DE LA SOCIEDAD ESPAÑOLA DE NEFROLOGÍA Y VII IBEROAMERICANO DE NEFROLOGÍA

Guideline Therapeutics and COVID-19: living guideline
Guideline Therapeutics and COVID-19: living guideline

Human ACE2 Peptide-Attached Plasmonic-Magnetic Heterostructure for Magnetic  Separation, Surface Enhanced Raman Spectroscopy Identification, and  Inhibition of Different Variants of SARS-CoV-2 Infections | ACS Applied Bio  Materials
Human ACE2 Peptide-Attached Plasmonic-Magnetic Heterostructure for Magnetic Separation, Surface Enhanced Raman Spectroscopy Identification, and Inhibition of Different Variants of SARS-CoV-2 Infections | ACS Applied Bio Materials

SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion | Nature
SARS-CoV-2 B.1.617.2 Delta variant replication and immune evasion | Nature

XXXVII Congreso SETH 2021.indd
XXXVII Congreso SETH 2021.indd

XXXVII Congreso SETH 2021.indd
XXXVII Congreso SETH 2021.indd

Guideline Therapeutics and COVID-19: living guideline
Guideline Therapeutics and COVID-19: living guideline

Guideline Therapeutics and COVID-19: living guideline
Guideline Therapeutics and COVID-19: living guideline

Structural basis of SARS-CoV-2 Omicron immune evasion and receptor  engagement | Science
Structural basis of SARS-CoV-2 Omicron immune evasion and receptor engagement | Science

EL VALOR DEL MEDICAMENTO DESDE UNA PERSPECTIVA SOCIAL
EL VALOR DEL MEDICAMENTO DESDE UNA PERSPECTIVA SOCIAL

Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised  patients treated with bamlanivimab in Germany - The Lancet Regional Health  – Europe
Emergence of the E484K mutation in SARS-COV-2-infected immunocompromised patients treated with bamlanivimab in Germany - The Lancet Regional Health – Europe